HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Finger-Prick Tests Show Antibody Response to SARS-CoV-2 Reduces Over Time

By HospiMedica International staff writers
Posted on 28 Oct 2020
Illustration
Illustration
Tests conducted on more than 365,000 people in the UK have shown that the antibody response to the SARS-CoV-2 virus that causes COVID-19 wanes over time.

Scientists from the Imperial College London (London, UK) conducted an analysis of finger-prick tests to detect coronavirus antibodies in the blood. When present these indicate that a person has been previously infected with the virus. The testing kits, called Lateral Flow Tests, detect antibodies above a particular concentration in the blood, and do not measure the amount of antibodies in a particular person. The tests are sent out to randomly-selected adult volunteers across the UK to carry out at home.

The latest report includes findings from three rounds of testing carried out over a three-month period. There were 17,576 positive results across all three rounds, around 30% of whom did not report any COVID-19 symptoms. After accounting for the accuracy of the test, confirmed by laboratory evaluation, and the country’s population characteristics, the study found that antibody prevalence declined from 6.0% to 4.8% and then 4.4% over the three months. This was found across all ages but the smallest drop was found in the youngest age group, aged 18-24, falling from 7.9% to 6.7% (14.9%), while the largest was found in the oldest group, aged 75 and above, declining from 3.3% to 2.0% (39%).

All parts of the UK showed a fall in prevalence, except the West Midlands which increased in round two and then declined in round three. London maintained the highest prevalence of antibodies across the different rounds, with 9% testing positive in round three, compared with the South West which consistently had the smallest proportion. The decline was largest in people who did not report a history of COVID-19, dropping by almost two-thirds (64.0%) between rounds one and three, compared to a decrease of 22.3% in people who had an infection confirmed by lab testing. Health and care workers, ethnic minority groups, and those living in deprived areas and large households also had the greatest burden of past infection. These findings suggest that there may be a decline in the level of immunity in the population in the months following the first wave of the epidemic.

“Our study shows that over time there is a reduction in the proportion of people testing positive for antibodies. It remains unclear what level of immunity antibodies provide, or for how long this immunity lasts,” said Professor Paul Elliott study author, Imperial College London.

“This very large study has shown that the proportion of people with detectable antibodies is falling over time. But we don’t yet know whether this will leave these people at risk of reinfection with the virus that causes COVID-19,” added Prof Helen Ward study author, Imperial College London.

Related Links:
Imperial College London

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Digital Color Doppler Ultrasound System
MS22Plus

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more